South East Asia Defibrillators Market To Reach $371.88 Million By 2030

 

The South East Asia Defibrillators Market size is anticipated to reach USD 371.88 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 8.83% from 2024 to 2030. The SEA defibrillator market’s growth is propelled by several critical factors, including technological advancements, rising cases of cardiac arrests, favorable government initiatives and healthcare policies.

Physical inactivity is a major public health concern as it has led to the second-highest number of deaths after the consumption of tobacco globally. A sedentary lifestyle leads to morbidity and the development of chronic conditions, such as diabetes and cardiac disorders. Physical inactivity is often associated with aggravation of symptoms of chronic conditions, including atherosclerotic and diabetic patients. Major consequences of this lifestyle are cardiac disorders, such as myocardial infarction, stroke, and angina. Most of the population suffering from cardiac disorder symptoms are thus advised at least 150 minutes of physical activity daily with a minimum of 75 minutes, especially in men. According to WHO, around 2 million people die annually due to physical inactivity, and around 60.0% to 85.0% of individuals globally follow sedentary lifestyles, making it a major public health concern.

Defibrillators such as implantable cardioverter defibrillators (ICDs), automated external defibrillators (AEDs), and wearable cardioverter defibrillators, cater to a diverse range of patients from adults to pediatrics. The demand for defibrillators in SEA is on the rise due to increasing awareness of cardiovascular diseases and sudden cardiac arrest incidents. This growing demand drives imports as local manufacturing may not meet the required supply levels. According to Volza Philippines Import data, 982 defibrillator shipments were imported by 155 Philippine Importers from 235 Suppliers, primarily from China, Hong Kong, and the United States. The top importers were India, Vietnam, and Brazil.

List of Key Players in the South East Asia Defibrillators Market

• Medtronic
• St. Jude Medical, LLC
• Boston Scientific Corporation
• Philips
• Zoll Medical Corporation
• Cardiac Science
• Physio-Control Inc.
• Nihon Kohden Corporation
• Progetti Srl
• FUKUDA DENSHI
• Schiller AG

Request a free sample copy or view report summary: South East Asia Defibrillators Market Report

South East Asia Defibrillators Market Report Highlights

• Based on product, the external defibrillator segment commanded the most significant revenue share, accounting for 53.61%, in 2023
• The growing elderly population, the incorporation of advanced technology, increased investments from both government and private manufacturers, and heightened awareness campaigns about cardiovascular disorders all contribute to the increased utilization of external defibrillators, propelling the growth of the external defibrillator segment
• Based on end use, the hospital segment is dominant due to its investment in advanced technology to enhance emergency response capabilities and maintain compliance with global healthcare standards

South East Asia Defibrillators Market Report Scope

Report Attribute	Details
Revenue forecast in 2024	USD 223.85 million
Revenue forecast in 2030	USD 371.88 million
Growth rate	CAGR of 8.83% from 2024 to 2030
Actual data	2018 - 2023
Forecast period	2024 - 2030

 

Related Press Release@ South East Asia Defibrillators Market Analysis

South East Asia Defibrillators Market Segmentation

Grand View Research has segmented the South East Asia defibrillators market based on product, end use, and region:

SEA Defibrillator Product Outlook (Revenue, USD Million, 2018 - 2030)

• Implantable Cardioverter Defibrillator (ICD)
• S-ICD
• T-ICD

• Single Chamber
• Dual Chamber
• CRT-D
• External Defibrillator
• Manual ED
• Automated ED
• Wearable cardioverter defibrillators

SEA Defibrillator End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital
• Pre hospital
• Public Access market
• Alternate care market
• Home healthcare

SEA Defibrillator Regional Outlook (Revenue, USD Million, 2018 - 2030)

• South East Asia
• Singapore
• Philippines
• Thailand
• Malaysia
• Indonesia
• Rest of South East Asia

Explore Horizon, the world's most expansive market research database

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Humanoid Robot Market by HYULIM Robot Co., Ltd; HANSON ROBOTICS LTD; Engineered Arts Limited; Honda; KAWADA Robotics Corporation

 The global Humanoid Robots Market size is expected to reach USD 4.04 billion by 2030, registering a CAGR of 17.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The global market for humanoid robots is poised for substantial growth due to rapid technological advancements leading to more efficient and affordable robot models. Furthermore, the increasing adoption of humanoid robots in military and defense applications, is expected to drive market expansion. Additionally, In addition, the growing trend of industry automation is anticipated to further fuel the demand for humanoid robots in various sectors.

Healthcare personnel are using humanoid robots to help in a variety of duties, including patient care, physical therapy, and monitoring. They can be designed to carry out monotonous activities, minimizing the workload on medical staff and increasing productivity all around with a variety of duties, including patient care, physical therapy, and monitoring. They can be designed to carry out monotonous activities, minimizing the workload on medical staff and increasing productivity overall. For example, Fourier GR-1, a mass-produced humanoid robot developed by Fourier Intelligence, can carry patients from bed to wheelchair and help pick up objects.

Moreover, there are some cutting-edge humanoid robots being employed in operations. They provide tremendous dexterity and precision, allowing surgeons to carry out intricate procedures with more accuracy and less intrusiveness. Humanoid robot advancements are being driven by ongoing research and development in the field of some cutting-edge humanoid robots are being employed in operations. They provide tremendous dexterity and precision, allowing surgeons to carry out intricate procedures with greater accuracy and less intrusiveness. Humanoid robot advancements are being driven by ongoing research and development in robotics, making them more versatile and specialized for healthcare purposes.

The industry industry's key players have focused on renting out their humanoids in an effort toto promote the use of the technology. For example, in December 2019, CloudMinds created a smart robot rental program that provides humanoid robots with cloud-based intelligence for entertainment at weddings, special events, conferences, trade exhibitions, and workplaces. With ambitions for robots like Cloud Patrol, Cloud Vending, Cloud Cleaning, and Cloud Assistant, the rental program began with the Cloud Pepper robot, which is well-known across several worldwide industry verticals. This would raise awareness of the advantages of technology and encourage more people to adopt it.

Moreover, the novel product launch are proposed by the industry players to enhance the product portfolio boosts industry players propose novel product launches to enhance the product portfolio and boost the market. For instance, in July 2023, Fourier Intelligence intends to produce 100 of its GR-1 universal humanoid robots by the end of 2023, ensuring the incredible claim that these machines will be able to lift nearly their own weight, in response to the growing need for healthcare during labor shortages and an aging population. They have a distinct focus as well. The GR-1 humanoid will be able to help pick up goods and transfer people from beds to wheelchairs.

List of key Players in the Humanoid Robots Market

• HYULIM Robot Co., Ltd
• HANSON ROBOTICS LTD
• Engineered Arts Limited
• Honda
• KAWADA Robotics Corporation
• SoftBank Robotics
• Sanbot Co
• ROBOTIS
• Willow Garage
• Toshiba Corporation

Request a free sample copy or view report summary: Humanoid Robot Market Report

Humanoid Robot Market Report Highlights

• By component, the hardware segment dominated the market in terms of revenue share in 2023. The creation ofCreating more sophisticated actuators and motors allowed humanoid robots to move more fluidly, with greater dexterity, and perform better overall.
• By application, the personal assistance and caregiving segment held the largest market share in 2023. These robots can be instructed to carry out basic domestic duties such as cooking, cleaning, and organizing, which eases the strain on individuals and families. Robots can also help with therapeutic tasks, including physical therapy exercises and entertainment for patients to ease their tension and anxiety, increasing segment growth.
• By motion type, the wheel drive segment dominated the market in terms ofregarding revenue share in 2023. These robots are used as entertainment in theme parks, scientific fairs, and amusement parks. Such factors are anticipated to fuel the segment growth over the forecast period.
• North America dominated the global humanoid robot market owing to the high demand for themdue to their high demand. This demand was caused by several factors, including an aging population, the need for personalized customer service, and the culture's emphasis on technology and innovation.

Humanoid Robot Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 1.55 billion
Revenue forecast in 2030	USD 4.04 billion
Growth rate	CAGR of 17.3% from 2023 to 2030
Historical data	2018 - 2023
Forecast data	2024 - 2030

 

Related Press Release@ Humanoid Robot Market

Humanoid Robots Market Segmentation

Grand View Research has segmented the global humanoid robots market on the basis of component, application, motion type based on component, application, motion type, and region:

Humanoid Robot Component Outlook (Revenue, USD Million, 2018 - 2030)

• Hardware
• Software

Humanoid Robot Application Outlook (Revenue, USD Million, 2018 - 2030)

• Research and Space Exploration
• Education and Entertainment
• Personal Assistance and Caregiving
• Hospitality
• Search and Rescue
• Others

Humanoid Robot Motion Type Outlook (Revenue, USD Million, 2018 - 2030)

• Biped
• Wheel drive

Humanoid Robot Regional Outlook (Revenue, USD Million, 2018 - 2030­)

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Norway
• Denmark
• Sweden
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Explore Horizon, the world's most expansive market research database

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Onychomycosis Market by Bausch Health Companies Inc.; GSK plc; Abbott; Pfizer Inc.; Bayer AG; Teva Pharmaceutical Industries Ltd.

 The global Onychomycosis Market size is estimated at USD 4.94 Billion in 2030 and is expected to grow at a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

List of Key Players in Onychomycosis Market

• Bausch Health Companies Inc.
• GSK plc
• Abbott
• Pfizer Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Merck & Co., Inc.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.

Request a free sample copy or view report summary: Onychomycosis Market Report

Onychomycosis Market Report Highlights

• Distal subungual onychomycosis segment dominated the market in 2022 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
• Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
• Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
• North America held the largest market share in 2022 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment

Onychomycosis Market Report Scope 

Report Attribute	Details
Market size value in 2024	USD 3.81 billion
Revenue forecast in 2030	USD 4.94 billion
Growth rate	CAGR of 4.4% from 2024 to 2030
Actual data	2018 - 2023
Forecast period	2024 - 2030

 

Related Press Release@ Onychomycosis Industry Analysis

Onychomycosis Market Segmentation

Grand View Research has segmented the global onychomycosis market based on the type, treatment, and region 

Onychomycosis Type Outlook (Revenue, USD Million, 2018 - 2030)

• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Other Types

Onychomycosis Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Oral
• Topical
• Others

Onychomycosis Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Explore Horizon, the world's most expansive market research database

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Veterinary Parasiticides Market Size is Predicted to Witness 8.50% CAGR till 2030

The global Veterinary Parasiticides Market size is expected to reach USD 16.63 billion by 2030, registering a CAGR of 8.50% from 2024 to 2030, according to a new report by Grand View Research, Inc. Primary market growth drivers include rising demand for pathogen-free meat products and the need for a regulated approach towards parasiticides use. In recent years, with increasing meat consumption, it has been observed that transmission of diseases from meat products has increased. According to an August 2023 study published in the International Journal of Food Microbiology, out of the total studied disease outbreaks from 1991 to 2021, the majority, i.e., 42.4%, were transmitted through meat production establishments. Regarding types of meat, beef & pork were identified to be responsible for 62.35% & 32.1% of the outbreaks, respectively. Such incidences have led to a rise in demand for pathogen-free meat products.

In response, meat producers are employing various strategies before harvesting the meat from the animals to reduce the risk of transmission of foodborne pathogens. Some of these strategies are reducing the number of pathogens entering processing plants, reducing horizontal pathogen spread from infected animals during transport, reducing the pathogen burden in the environment (e.g., dust and pen surfaces), and administering proper treatment regimens to the animals to reduce the risk of getting infected.

Furthermore, animal farms are also breeding & raising specific pathogen-free (SPF) animals free of selected pathogens like parasites, bacteria & viruses, which can potentially transmit diseases to humans. A history of regular pathogen testing and meticulous biosecurity planning for managing housing, environmental, and husbandry factors is essential for producing and preserving SPF animals. Comprehensive risk analysis and exclusion procedures based on an in-depth understanding of the pathogen lifecycle and modes of transmission are vital elements of successful programs. These SPF animals, like pigs, cattle, and poultry, can be used in producing pathogen-free dairy and meat and research activities.

This is a major market driver because, as the production and demand for pathogen-free meat products increase, so will the requirement for products like parasiticides to eliminate the harmful pathogens from these animals and produce a healthy and pathogen-free yield.

However, a major factor that could hamper market growth is the development of antiparasitic drug resistance among animals. In recent years, various research studies have started revealing the rise in antiparasitic drug resistance among animals. For instance, a March 2023 study by the University of Calgary revealed a consistent rise in drug resistance among gastrointestinal worms in the studied pet dogs. Until now, antiparasitic resistance wasn’t considered a major problem among companion animals. However, this growing resistance points towards the fact that in the near future, many routine drug treatments may be ineffective. Therefore, selective use of antiparasitic drugs and thorough research into revealing such instances in other animals is required to resist the negative impact of this factor on the market.

List of Key Players of Veterinary Parasiticides Market

• Zoetis
• Boehringer Ingelheim
• Merck & Co. Inc.
• Dechra Pharmaceuticals Plc.
• Elanco Animal Health
• Ceva Sante Animale
• Virbac
• Biogénesis Bagó
• Vetoquinol
• Himalaya Wellness

Request a free sample copy or view report summary: Veterinary Parasiticides Market Report

Veterinary Parasiticides Market Report Highlights

• Based on animal type, the production animal segment held the dominant revenue share of 58.21% in in 2023. This growth can be attributed to increasing demand for animal products and the use of parasiticides in the prevention and treatment of parasitic infections among production animals.
• Based on product, the ectoparasiticides segment dominated the market with a revenue share of 48.81% in 2023. Ectoparasiticides are preferred over endectocides for treating external parasites like ticks, fleas, and lice due to their targeted action and cost-effectiveness. These products come in various formulations like sprays, powders, ointments, creams, and spot-on treatments. These multiple formulations give these products the advantage over others, as animal owners and veterinary professionals can easily choose the formulation that best suits the target animal.
• Based on the route of administration, the topical segment dominated market with a revenue share of over 40% in 2023. This can be attributable to the fact that this route of administration is primarily used to treat external parasites like ticks, fleas, and worms in animals through ectoparasiticides. The external application ensures that the parasiticides deal only with the external parasites on the animal's skin and fur and do not directly interact with other essential organisms in animals, minimizing the possible side effects.
• Based on the distribution channel, the hospital/clinic pharmacy segment dominated the market in 2023. This can be attributable to the availability of a wide variety of parasiticides in these settings. Various animals, such as horses, dogs, cats, and livestock, visit these hospitals/clinics to treat various diseases. After the consultation and diagnosis, the veterinarian can prescribe the required medications to the animal owners, which they can easily procure from the pharmacy present at the hospital or clinic.
• North America accounted for the largest revenue share in 2023 and is expected to grow at a significant CAGR from 2024 to 2030. This is attributed to the fact that the region is among the top meat-producing countries and has the highest pet adoption rate in the world. These factors contribute to the region's rise in demand for parasiticide products.
• The Asia Pacific (APAC) market is expected to grow at the fastest CAGR from 2024 to 2030 due to growing initiatives to spread awareness about the diagnosis and treatment of veterinary parasitic infections. Recognizing the growing disease burden of parasitic infections and their zoonoses, the World Organization of Animal Health (WOAH) is actively arranging awareness initiatives to prevent and control parasitic infection zoonoses.

Veterinary Parasiticides Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 10.19 billion
Revenue forecast in 2030	USD 16.63 billion
Growth rate	CAGR of 8.50% from 2024 to 2030
Actual data	2018 - 2023
Forecast period	2024 - 2030

 

Related Press Release@ Veterinary Parasiticides Industry

Veterinary Parasiticides Market Segmentation

Grand View Research has segmented the global veterinary parasiticides market based on the animal type, product, route of administration, distribution channel, and region:

Veterinary Parasiticides Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

• Production Animal
• Cattle
• Swine
• Poultry
• Others (sheep, goats, aquaculture, etc.)
• Companion Animal
• Canine
• Feline
• Equine
• Others (turtles, fish, rabbit, etc.)

Veterinary Parasiticides Product Outlook (Revenue, USD Million, 2018 - 2030)

• Ectoparasiticides
• Endoparasiticides
• Endectocides

Veterinary Parasiticides Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral
• Injectable
• Topical

Veterinary Parasiticides Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Retail
• E-Commerce
• Hospital/ Clinic Pharmacy
• Others (government campaigns, etc.)

Veterinary Parasiticides Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• India
• China
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Explore Horizon, the world's most expansive market research database

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com